John P. Hayes
Experienced in Esophageal Cancer

Dr. John P. Hayes

Radiation Oncology
250 E Superior St Ste LC-2101, Prentice Women's Hospital, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
38 Years of Experience
Experienced in Esophageal Cancer
250 E Superior St Ste LC-2101, Prentice Women's Hospital, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Hayes is a Radiation Oncologist in Chicago, Illinois. Dr. Hayes has been practicing medicine for over 38 years and is rated as an Experienced provider by MediFind in the treatment of Esophageal Cancer. His top areas of expertise are Anal Cancer, Fibrosarcoma, Pancreatic Cancer, and Myxoid Liposarcoma.

His clinical research consists of co-authoring 30 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Esophageal Cancer.

Graduate Institution
West Virginia University School Of Medicine, 1987
Residency
McGaw Medical Center of Northwestern University
Specialties
Radiation Oncology
Licenses
Radiology in WI
Board Certifications
American Board Of Radiology - Radiation Oncology (Certified)
Hospital Affiliations
Northwestern Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

250 E Superior St Ste LC-2101, Prentice Women's Hospital, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Procedure, Other, Radiation
Study Drug: Peposertib
Study Phase: Phase 1/Phase 2
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: October 10, 2025
Intervention Type: Radiation, Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
A Phase Ib Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drug: MDM2 Inhibitor KRT-232
Study Phase: Phase 1
Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia
Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia
Enrollment Status: Terminated
Publish Date: February 03, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: April 24, 2024
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Enrollment Status: Completed
Publish Date: May 25, 2022
Intervention Type: Radiation
Study Phase: Phase 1
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: August 28, 2019
Intervention Type: Radiation
Study Phase: Phase 3
View 7 Less Clinical Trials

30 Total Publications

A deep learning model for preoperative risk stratification of pancreatic ductal adenocarcinoma based on genomic predictors of liver metastasis.
A deep learning model for preoperative risk stratification of pancreatic ductal adenocarcinoma based on genomic predictors of liver metastasis.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 04, 2025
Similar Doctors
Advanced in Esophageal Cancer
Dr. Najeeb M. Mohideen
Radiation Oncology
Advanced in Esophageal Cancer
Dr. Najeeb M. Mohideen
Radiation Oncology

Radiation Oncology Associates LLC

800 W Central Rd, 
Arlington Heights, IL 
 (22.7 miles away)
847-618-6570
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Najeeb Mohideen is a Radiation Oncologist in Arlington Heights, Illinois. Dr. Mohideen is rated as a Distinguished provider by MediFind in the treatment of Esophageal Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Endometrial Cancer, and Anal Cancer. Dr. Mohideen is currently accepting new patients.

Experienced in Esophageal Cancer
Dr. Aditya Juloori
Radiation Oncology
Experienced in Esophageal Cancer
Dr. Aditya Juloori
Radiation Oncology

The University Of Chicago

5841 S Maryland Ave, 
Chicago, IL 
 (7.4 miles away)
773-702-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Aditya Juloori is a Radiation Oncologist in Chicago, Illinois. Dr. Juloori is rated as a Distinguished provider by MediFind in the treatment of Esophageal Cancer. His top areas of expertise are Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Laryngeal Cancer. Dr. Juloori is currently accepting new patients.

Experienced in Esophageal Cancer
Dr. Harish V. Thakrar
Radiology | Radiation Oncology
Experienced in Esophageal Cancer
Dr. Harish V. Thakrar
Radiology | Radiation Oncology
161 E Chicago Ave, # 52 B, 
Chicago, IL 
 (0.5 miles away)
312-642-6006
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Harish Thakrar is a Radiologist and a Radiation Oncologist in Chicago, Illinois. Dr. Thakrar is rated as an Advanced provider by MediFind in the treatment of Esophageal Cancer. His top areas of expertise are Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and ALK-Positive Non-Small Cell Lung Cancer. Dr. Thakrar is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hayes's expertise for a condition
ConditionClose
    View All 20 Advanced Conditions
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile